Syncan project to confirm BeneoSynergy's benefits against colon cancer

Belgium's ORAFTI, the ingredients business of German sugar giant the Sudzucker group, says that the a new study may confirm whether or not its Beneo Synergy1 product modulates against the risk of colon cancer. The trial builds on data from the European Union-funded Syncan project, initiated in 2001, which suggested that a combination of the additive and probiotic bacteria can reduce various risk factors associated with the disease.

The new study is being carried out through the US Cancer Prevention Network, a research consortium funded by the National Cancer Institute that is based at the Mayo Clinic in Rochester, Minnesota. The work forms part of a program of three clinical trials that are designed to examine the use of non-steroidal anti-inflammatory drugs in the prevention of cancers of the oesophagus, lung and colon.

Beneo Synergy1 promotes colon health